These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12137808)

  • 1. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells.
    Ehmer PB; Bureik M; Bernhardt R; Müller U; Hartmann RW
    J Steroid Biochem Mol Biol; 2002 Jun; 81(2):173-9. PubMed ID: 12137808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
    Bureik M; Hübel K; Dragan CA; Scher J; Becker H; Lenz N; Bernhardt R
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):249-54. PubMed ID: 15134825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
    Ulmschneider S; Müller-Vieira U; Mitrenga M; Hartmann RW; Oberwinkler-Marchais S; Klein CD; Bureik M; Bernhardt R; Antes I; Lengauer T
    J Med Chem; 2005 Mar; 48(6):1796-805. PubMed ID: 15771425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
    Müller-Vieira U; Angotti M; Hartmann RW
    J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):259-70. PubMed ID: 15985365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of a whole-cell based medium throughput screening system for the discovery of human aldosterone synthase (CYP11B2) inhibitors: old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
    Hakki T; Hübel K; Waldmann H; Bernhardt R
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):120-8. PubMed ID: 21193036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors.
    Mangelis A; Jühlen R; Dieterich P; Peitzsch M; Lenders JWM; Hahner S; Schirbel A; Eisenhofer G
    J Steroid Biochem Mol Biol; 2019 Apr; 188():38-47. PubMed ID: 30529282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors.
    LaSala D; Shibanaka Y; Jeng AY
    Anal Biochem; 2009 Nov; 394(1):56-61. PubMed ID: 19622340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human.
    Cerny MA; Csengery A; Schmenk J; Frederick K
    J Steroid Biochem Mol Biol; 2015 Nov; 154():197-205. PubMed ID: 26303746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis.
    Hartmann RW; Müller U; Ehmer PB
    Eur J Med Chem; 2003 Apr; 38(4):363-6. PubMed ID: 12750023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1.
    Bureik M; Schiffler B; Hiraoka Y; Vogel F; Bernhardt R
    Biochemistry; 2002 Feb; 41(7):2311-21. PubMed ID: 11841224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.
    Grombein CM; Hu Q; Rau S; Zimmer C; Hartmann RW
    Eur J Med Chem; 2015 Jan; 90():788-96. PubMed ID: 25528333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the fungicide epoxiconazole by virtual screening and biological assessment as inhibitor of human 11β-hydroxylase and aldosterone synthase.
    Akram M; Patt M; Kaserer T; Temml V; Waratchareeyakul W; Kratschmar DV; Haupenthal J; Hartmann RW; Odermatt A; Schuster D
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105358. PubMed ID: 30965118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
    Bogman K; Schwab D; Delporte ML; Palermo G; Amrein K; Mohr S; De Vera Mudry MC; Brown MJ; Ferber P
    Hypertension; 2017 Jan; 69(1):189-196. PubMed ID: 27872236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
    Ulmschneider S; Müller-Vieira U; Klein CD; Antes I; Lengauer T; Hartmann RW
    J Med Chem; 2005 Mar; 48(5):1563-75. PubMed ID: 15743198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
    Zimmer C; Hafner M; Zender M; Ammann D; Hartmann RW; Vock CA
    Bioorg Med Chem Lett; 2011 Jan; 21(1):186-90. PubMed ID: 21129965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activity.
    Meyers K; Cogan DA; Burke J; Arenas R; Balestra M; Brown NF; Chen Z; Cerny MA; Clifford HE; Colombo F; Fader L; Frederick KS; Guo X; Goldberg D; Hornberger KR; Kugler S; Lord J; Marshall DR; Moss N; Parmentier JH; Richman JR; Schmenk J; Weldon SM; Yu M; Zhang M
    Bioorg Med Chem Lett; 2018 Mar; 28(5):979-984. PubMed ID: 29254646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Novel Pyrazole-Based Selective Aldosterone Synthase (CYP11B2) Inhibitors: A New Template to Coordinate the Heme-Iron Motif of CYP11B2.
    Sakakibara R; Sasaki W; Onda Y; Yamaguchi M; Ushirogochi H; Hiraga Y; Sato K; Nishio M; Egi Y; Takedomi K; Shimizu H; Ohbora T; Akahoshi F
    J Med Chem; 2018 Jul; 61(13):5594-5608. PubMed ID: 29878770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo.
    Ries C; Lucas S; Heim R; Birk B; Hartmann RW
    J Steroid Biochem Mol Biol; 2009 Sep; 116(3-5):121-6. PubMed ID: 19427380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disorders of the aldosterone synthase and steroid 11beta-hydroxylase deficiencies.
    Peter M; Dubuis JM; Sippell WG
    Horm Res; 1999; 51(5):211-22. PubMed ID: 10559665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of sulfonylpyrimidines as novel selective aldosterone synthase (CYP11B2) inhibitors.
    Meguro M; Miyauchi S; Kanao-Arisumi Y; Naito S; Suzuki K; Inoue S; Yamada K; Homma T; Chiba K; Nara F; Furuzono S
    Bioorg Med Chem; 2024 Jun; 108():117775. PubMed ID: 38851000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.